Teruhisa Fujii

Last Updated :2024/04/03

Affiliations, Positions
Hiroshima University Hospital, Associate Professor
Web Site
E-mail
teruchanhiroshima-u.ac.jp
Other Contact Details
1-2-3, Kasumi, MInami-ku, Hiroshima city, Japan, Japan
TEL : (+81)082-257-555 FAX : (+81)082-257-558
Self-introduction
After graduating from Hiroshima University, I have worked at Hiroshima University Hospital from 1997. I specialized in Hematology, especially , the field of thrombosis and hemostasis as well asTransfusion Medicine. I am also the head of Hemophilia Treatment center, which was established in Hiroshima University Hospital in 2018.

Basic Information

Major Professional Backgrounds

  • 2007/04/01, 2010/03/31, Division of Blood Transfusion , Hiroshima University Hospital, Assistant profesor, Hiroshima Universty

Educational Backgrounds

  • Hiroshima University, Graduate School, Division of Medicine, Japan, 1994/04, 1997/03
  • Hiroshima University, Faculty of Medicine, Japan, 1984/04, 1991/03

Academic Degrees

  • Doctor of Philosophy in Medical Science, Hiroshima University

Educational Activity

  • [Bachelor Degree Program] School of Medicine : Program of Medicine : Medicine

In Charge of Primary Major Programs

  • Medicine

Research Fields

  • Medicine,dentistry, and pharmacy;Clinical internal medicine;Hematology

Research Keywords

  • guidline
  • hemophilia
  • transfusion
  • inhibitor
  • HIV
  • CD4
  • aging

Affiliated Academic Societies

  • The Japanese Society of Hematology, 1993/05
  • The Japanese Society of Transfusion Medicine and cell therapy, 2001/01
  • The Japanese Society for AIDS Research
  • The Japanese Society on Thrombosis and Hemostasis
  • The Japanese Association for Infectious Disease
  • International Society on Thrombosis and Hemostasis, 2011/06
  • World Federation of Hemophilia, 2008/03
  • The Japanese Society of Internal Medicine
  • The Japanese Society for Laboratory Hematology, 2015/07

Educational Activity

Course in Charge

  1. 2024, Undergraduate Education, Year, Clinical diagnosis and treatment II
  2. 2024, Undergraduate Education, Year, Systemic Disease Control
  3. 2024, Undergraduate Education, Intensive, Practice of Medicine I
  4. 2024, Undergraduate Education, Intensive, Practice of Medicine II

Research Activities

Academic Papers

  1. The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacs, Molecular therapy, 27, 404-414, 2022
  2. Evaluation of physical function of adult patients with hemophilia by physiotherapist at summer camp, J Physc Ther Prac Res, 30, 127-128, 2022
  3. Perioperative Management of Hemophilia A With Recombinant VIII-SingleChain: A Case Series, J Curr Surg, 12(1), 15-20, 202201
  4. A PWH/A who developed autoimmune hemolytic anemia after the start of antiviral therapy: A case report., 70(3), 200-203, 2022
  5. Safety and efficacy of albutrepenonacog alfa in patients with hemophilia B: Interim report on the use performance survey in Japan, Jpn J Thromb Hemst, 33(1), 60-68, 20220201
  6. The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacs, MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 27, 404-414, 20221208
  7. Clinical conditions and risk factors for inhibitor-development in patients with haemophilia: A decade-long prospective cohort study in Japan, J-HIS2 (Japan Hemophilia Inhibitor Study 2), HAEMOPHILIA, 28(5), 745-759, 202209
  8. Mothers' strategies for supporting daughters who are potential haemophilia carriers., Haemophilia, 28(3), e91-e94, 2022
  9. Inter-observer reliability of three different radiographic scores for adult haemophilia, HAEMOPHILIA, 17(1), 134-138, 201101
  10. A case of HIV encephalitis with subacute progressive memory and gait disturbance, Journal of Japan society of internal medicine, 84, 120-121, 19950401
  11. Analysis of peripheral blood and brouchoalveolar lavage fluid cells in a patient with ATL, The Journal of Hiroshima Medical Association, 48, 439-444, 19950401
  12. Plasma cells composing plasmacytoma have phenotypes different from those of myelowa cells, American Journal of Hematology, 53, 251-253, 19960401
  13. Evaluation of the change of bleeding episodes in hemophiliac patients with HIV infectiou after medication of protease inhibitors., AIDS Research Newsletter, 11, 34, 19970401
  14. Change in viral DNA and mRNA burdens in peripheral blood mononuclear cells in a patients with HIV-1 after stopping anti-retroviral treatment., Journal of AIDS Research, 4(3), 104-107, 20020401
  15. Plasma cells composing plasmacytoma have phemotype different from those of myeloma cells, Am. J. Hematol. =, 53, 251-253, 19960401
  16. A point mutation in gycoprotein IX coding sequence causes impared surface expression of GP Ib/IX/V complex in two families with Bernard-Soulier syndrome, Thoromb Haemost, 76, 874-878, 19960401
  17. Oligoclonal accumulation of T cells in peripheral blood from patients with idiopathic thrombocytopenic purpura, Brit. J. Haematol.=, 95, 732-737, 19960401
  18. Potential interaction between ritonavir and carbamazepine, PHARMACOTHERAPY, 20, 851-854, 20000401
  19. Change in plasma viral load, and viral DNA and mRNA burdens, in peripheral blood mononuclear cells from patients infected with HIV-1, J. Infection, 42(1), 20-26, 20010401
  20. A point mutation Glycoprotein IX coding sequence(Cys73(TGT) to Tyr (TAT)) causes impaired surface expression of GPIb/IX/V complex in two families with Bernard-Soulier Syndrome., Thrombosis and Haemostasis, 76, 874-878, 19960401
  21. Usefulness of Improved Measurement of Platelet RNA Stained with Thizole Orange (T.O); High Percentage of T.O. Positive Platelet is Distinctive Feature of ITP when Compared with Chronic Thrombocytopenia Caused by Other Disorders., 38th Annual Meeting of the American Society of Hematology December 6-10(7) = Orlando= Florida, 88 2/2, supplement 59b, 19960401
  22. The change of HIV-1 proviral DNA copy number in peripheral blood mononuclear cells during anti-HIV therapies, 12th World AIDS Conference, 19980401
  23. CD4 Viral Load Discrepancy, J. AIDS Research, 54(10), 837-841, 20010401
  24. ABO major mismatch, 16(10), 1145-1150, 20040901
  25. ★, Management of haemostasis during hemodialysis in a patient with haemophilia B, HAEMOPHILIA, 14(5), 1135-1137, 20080101
  26. ★, A new approach to detect reticulated platelets stained with Thiazole Orange in thrombocytopenic patients, THROMBOSIS RESEARCH, 97(6), 431-440, 20000315
  27. Disseminated mucormycosis in an acquired immunodeficiency syndrome (AIDS) patient, INTERNAL MEDICINE, 42(1), 129-130, 200301
  28. HLA-B polymorphism in Japanese HIV-1-infected long-term surviving hemophiliacs, VIRAL IMMUNOLOGY, 18(3), 500-505, 200503
  29. Abacavir/Lamivudine versus Tenofovir/Emtricitabine with Atazanavir/Ritonavir for Treatment-naive Japanese Patients with HIV-1 Infection: A Randomized Multicenter Trial, INTERNAL MEDICINE, 52(7), 735-744, 2013
  30. ★, Switching Tenofovir/Emtricitabine plus Lopinavir/r to Raltegravir plus Darunavir/r in Patients with Suppressed Viral Load Did Not Result in Improvement of Renal Function but Could Sustain Viral Suppression: A Randomized Multicenter Trial, PLOS ONE, 8(8), 20130808
  31. A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics, HAEMOPHILIA, 19(6), 853-860, 201311
  32. Postsurgical coagulopathy in a hemophilia A patient with inhibitors: efficacy of recombinant factor VIIa, JOURNAL OF ANESTHESIA, 28(4), 621-624, 201408
  33. Plasma concentration of cartilage oligomeric matrix protein(COMP) in hemophilic patients., HAEMOPHILIA, 14(supl), 22-22, 2008
  34. THE JAPANESE GUIDELINE FOR THE HEMOSTATIC THERAPY OF PATIENTS WITH CONGENITAL HEMOPHILIA AND INHIBITORS , J Thrombosis and Haemostasis, 7(supple2), 526-526, 2009
  35. Inter-observer reliability of three different radiographic evaluation systems for haemophilic arthropathy, Haemophilia, 16(suppl4), 26-26, 2010
  36. Relationship between haemarthrosis and haemophilic arthropathy, Haemophilia, 16(suppl4), 27-27, 2010
  37. Long-term clinical safety of FEIBA, activated prothrombin complex concentrate (APCC) in Japanese inhibitor subjects: an update of postauthorization safety surveillance (PASS) program, Haemophilia, 16(suppl4), 31-31, 2010
  38. Hemostatic management for intractable trraumatic hemorrhage using fibrinogen concentrates and recombinant actvated factor VII, THE JAPANESE JOURNAL OF CLINICAL HEMATOLOGY, 55(2), 234-237, 2014
  39. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A, J Thrombosis and Haemostasis, 13, 9-10, 201506
  40. ★, A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors., Haemophilia, 1-8, 201608
  41. Three older adults with full-blown AIDS diagnosed only after pre-transfusion viral marker screening tests, J AIDS Research, 18(3), 224-229, 201508
  42. Efficacy of secondary prophylaxis on annual bleeding ratio (ABR) in adult patients with hemophilia:a single center observation study in Japan., J Thrombosis and Haemostasis, 13(suppl), 346-346, 201506
  43. Barriers to inform hemophilic carriers of that possibility in Japan, J Thrombosis and Haemostasis, 13(suppl), 399, 201506
  44. A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors, HAEMOPHILIA, 23(1), 59-66, 201701
  45. Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product, INTERNATIONAL JOURNAL OF HEMATOLOGY, 105(3), 280-286, 201703
  46. Three older adults with full-blown AIDS diagnosed only after pre-transfusion viral marker screening tests, Journal of AIDS Research, 18(3), 224-229, 201606
  47. The bone metabolism abnormality of HIV infected patients and the factor influenced it an analysis in Hiroshima University Hospital, Journal of AIDS research, 19(1), 32-36, 201702
  48. Exited half life product for hemophilia, Japanese Journal of Thrombosis and Hemostasis, 28(4), 472-479, 201708
  49. Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations, INTERNATIONAL JOURNAL OF HEMATOLOGY, 106(5), 704-710, 201711
  50. Anti-human neutrophil antigen-1a,-1b, and-2 antibodies in neonates and children with immune neutropenias analyzed by extracted granulocyte antigen immunofluorescence assay, TRANSFUSION, 57(11), 2586-2594, 201711
  51. A case report on the successful perioperative management of hepatectomy for hepatocellular carcinoma in a patient with von Willebrand disease, INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS, 44, 131-134, 2018
  52. A Single Center Study of the Treatment Outcome of HCV and the Long-term Prognosis in Patients with HIV/HCV-Coinfection, The journal of the Japanese Association for Infectious Diseases, 91(6), 924-929, 201711
  53. ★, Ischaemic events are rare, and the prevalence of hypertension is not high in Japanese adults with haemophilia: First multicentre study in Asia, HAEMOPHILIA, 25(4), E223-E230, 201907
  54. Mothers' intentions and behaviours regarding providing risk communication to their daughters about their possibility of being haemophilia carriers: A qualitative study, HAEMOPHILIA, 25(6), 1059-1065, 201911
  55. Oral environment and taste function of Japanese HIV-infected patients treated with antiretroviral therapy, AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 32(7), 829-834, 20200702
  56. Brief HIV stigma scale for Japanese people living with HIV: validation and restructuring using questionnaire survey data., AIDS CARE, 28(1), 1-9, 2019
  57. Oral environment and taste function of Japanese HIV-infected patients treated with antiretroviral therapy., AIDS CARE, 27(7), 829-834, 2019
  58. Clinical Outcomes of Post-exposure Prophylaxis following Occupational Exposure to Human Immunodeficiency Virus at Dental Departments of Hiroshima University Hospital, CURRENT HIV RESEARCH, 18(6), 475-479, 2020
  59. Brief HIV stigma scale for Japanese people living with HIV: validation and restructuring using questionnaire survey data, AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 32, 1-9, 20201209
  60. Budget impact analysis of Jivi (damoctocog alfa pegol, Bay 94-9027) in severe hemophilia A in Japan, JOURNAL OF MEDICAL ECONOMICS, 24(1), 218-225, 20210101
  61. Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis, HEMATOLOGY, 26(1), 186-198, 20210101
  62. ★, Long-term impact of haemarthrosis on arthropathy and activities of daily living in Japanese persons with haemophilia, Haemophilia, 26(3), 124-127, 20200615
  63. ★, Weather changes leading to bleeding in arthropathic joints among individuals with haemophilia: symptoms of meteoropathy?, Haemophilia, 26(6), 346-248, 20201103
  64. Outcomes of Patients Who Undergo Transfusion of Fresh Frozen Plasma: A Prospective, Observational, Multicentre Cohort Study in Hiroshima, Japan, JOURNAL OF BLOOD MEDICINE, 12, 965-973, 2021

Invited Lecture, Oral Presentation, Poster Presentation

  1. Bleeding episodes in adult patients with hemophilia A who switched to prophylaxis with emicizumab, Teruhisa Fujii, Noya Yamasaki, Tomoko Ito, 2022/10, Without Invitation, Japanese
  2. TSUBASA: a prospective study evaluating the association between physical activity and bleeding events in people with hemophilia A during emicizumab, Teruhisa Fujii, Kagehiro Amano, Akihiro Sawada, Azusa Nagao, Chiai Nagae, Masanori Nojima, Nobuaki Suzuki, Daisuke Nosaka, Tomomi Shimura, Yoshimasa Sugao, Keiji Nogami, XXIV Congress of the International Society on Thromobosis and Haemostasis, 2022/05, Without Invitation, English, Montreal web
  3. The Parameters of Modified Clot Waveform Analysis Using the Plasmas of Hemophilia A Patients Treated with Emicizumab, N. Yamasaki, T.Fujii, K. Kajihara, H. Nakagawa, M. Yokozaki, XXVIII Congress of the International Society on Thromobosis and Haemostasis, 2020/07, Without Invitation, English, International Society of Thrombosis & Haemostasis, Milan, other
  4. BUDGET IMPACT ANALYSIS OF BAY-94 9027 (DAMOCTOCOG ALFA PEGOL) IN SEVERE HEMOPHILIA A (HA) IN JAPAN, Teruhisa Fujii, Yuko Kidoguchi, Noriko Takahashi, Eric Yu, Dilinuer Ainiwaer, Aidan Byrne, 2020/10, Without Invitation, English, Japan society of Hematology, kyoto, other
  5. Plasma factor VIII activity measured by coagulation one-stage and chromogenic assays in patients with hemophilia A treated with emicizumab, T.Fujii,, T.Fujii, N. Yamasaki,T. Inoue, XXVIII Congress of the International Society on Thromobosis and Haemostasis, 2020/07, Without Invitation, English, International Society of thrombosis & haemostasis, Milan, other
  6. Comparison of mindset between the medical doctors and the staffs of genetic counseling about support of hemophilia carriers in Japan, Tomie Fujii, Teruhisa Fujii, Yukiko MIYAKOSHI, XXVII Congress of the International Society on Thromobosis and Haemostasis, 2019/07/09, Without Invitation, English
  7. Extended half-life factor VIII management of hemophilia A undergoing surgery is not only efficient but also contributes to saving the factor consumption compared to standard half-life products., T.FUJII,T.Fujii, N. Yamasaki, XXVII Congress of the International Society on Thromobosis and Haemostasis, 2019/07/08, Without Invitation, English, nternational society of thrombosis & haemostasis, Melborne
  8. Psychosocial factors influencing continuation of medical attendance among Japanese HIV patients., Fumiko Kagiura, Fujii, T., Takayama, T, Jyozaki, M, Shimoji, Y., Kakehashi, M., The 4th International Association for the Social Sciences and Humanities in HIV Conference, 2018/07, Without Invitation, English, other
  9. Efficacy and safety of bolus infusions of rFVIII-Fc during the perioperative bleedings in two patients with hemophilia A., Naoya Yamasaki, Teruhisa Fujii, the 40th Congress of the Japanese Society on Thrombosis and Hemostasis, 2018/06, Without Invitation, English, APSTH, Sapporo, other
  10. The mothers’ thought and measures for the hemophilic carriers to notify their daughters in Japan, Tomie Fujii, Teruhisa Fujii, Sanae ORIYAMA, Yukiko MIYAKOSHI, XXXIII International Congress of the World Federation of Hemophilia, 2018/05, Without Invitation, English, World Federation of Hemophilia, Glasgow, UK
  11. Individualized prophylaxis can contribute to decreasing annualized bleeding ratio(ABR) in adult persons with hemophilia A, Teruhisa Fujii Naoya Yamasaki, Seiji Saito, Tomie Fujii, XXXIII International Congress of the World Federation of Hemophilia, 2018/05, Without Invitation, English, World Federation of Hemophilia, Glasgow, UK.
  12. Correlation between factor VIII or IX activity and APTT in patients with hemophilia patients, Naoya Yamasaki,Seiji Saito,Teruhisa Fujii, East Asia Hemophilia Forum, 2017/10, Without Invitation, English, Taichyun
  13. Is the result of Clot Waveform Analysis (CWA) different in hemophilia A and B?, Naoya Yamasaki, Teruhisa Fujii, The 79th congress Japanese society of hematology, 2017/10, Without Invitation, Japanese, other
  14. Should hemostatic ability of hemophilic patients be evaluated based on coagulation factor activity?, Naoya Yamasaki, Teruhisa Fujii, East Asia Hemophilia Forum, 2017/10, Without Invitation, English, other
  15. Can tertiary prophylaxis gring about zero bleeding in adult persons with hemophilia?, Teruhisa Fujii, Naoya Yamasaki, Seiji Saito,T Fujii, XXVI Congress of the International Society on Thromobosis and Haemostasis, 2017/07, Without Invitation, English, International society on thrombosis and hemostasis, Berlin, Germany, other
  16. Activated partial thromboplastin time (APTT) of persons with haemophilia A can serve as a surrogate marker of their factor VIII activity, Teruhisa Fujii, Naoya Yamasaki, Seiji Saito,T Fujii, XXXII International Congress of the World Federation of Hemophilia, 2016/07, Without Invitation, English, World Federation of Haemophilia, Orlando, Frorida
  17. Advocatiing scoring system to evaluate risk of intracranial hemorrhages in adult hemophilia, Seiji.Saito,, Naoya Yamasaki, Teruhisa.Fujii, 2016, Without Invitation, Japanese
  18. Influence of quantity of von Willebrand factor antigen in hemophilia A, Naoya Yamasaki, Seiji Saito, Teruhisa Fujii, 2016, Without Invitation, Japanese
  19. Sub-analysis of Japanese patietents with hemophilia B in rIX-FP clinical trial, Mitsuhiro Kuwabara, Hideji Hanabusa, Katsuyuki Fukutake, Kagehiro Amano, Masashi Taki, Jisin Yang, Midori Kobayashi, Koji Yamamoto, Tadashi Matsushita, Midori Shima, Keiji Nogami, Teruhisa Fujii, Satoshi Higasa, Michio Sakai, 2016, Without Invitation, Japanese
  20. The current status of prophylaxis in adult patients with hemophilia: an institution observation study, Seji Saito,Naoya Yamasaki,Teruhisa Fujii,Tatsuo Ichinohe, 2015/10, Without Invitation, English
  21. Correlation between factor VIII activity and APTT in patients with hemophilia A, Naoya Yamasaki,Seiji Saito,Teruhisa Fujii, 2015/10, Without Invitation, English
  22. Efficacy of secondary prophylaxis and consideration of the factors in adult patients with hemophilia, 2015/10, Without Invitation, Japanese
  23. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A, Lalezari S, Fujii T, Kwong YL, Delesen H, Shah A,Tu€ckmantel C, van Heerde W and Enriquez MM, XXV Congress of the International Society on Thromobosis and Haemostasis, 2015/06, Without Invitation, English
  24. Efficacy of secondary prophylaxis on annual bleeding ratio (ABR) in adult patients with hemophilia:a single center observation study in Japan. , 2015/06, Without Invitation, English
  25. Barriers to inform hemophilic carriers of that possibility in Japan, Fujii T, Murakami A, Fujii T and Miyakoshi Y, XXV Congress of the International Society on Thromobosis and Haemostasis, 2015/05, Without Invitation, English
  26. Influence of wether on joint bleedings and hemorrage reduction effect by prophylaxis in hemophilia, 2014/10, Without Invitation
  27. Does bad weather have a bad influence on joint bleedings in patients with haemophilic arthropathy?, 2014/05, Without Invitation
  28. “Moba-Roku”: use of a mobile recording system for tracking treatment infusions, 2014/05, Without Invitation
  29. The relationship with weather and joint bleedings in haemophilic patients. , 2013
  30. Dissimilarity of daily lives and joint damage between young and middle aged people with haemphlia in Japan., 2012
  31. Our Experience with Washed Platelet Products Manufactured in a Hospital, 2011
  32. Plasma concentration of cartilage oligomeric matrix protein(COMP) in hemophilic patients., 2008
  33. Current situation and prevention of HIV/AIDS, 2007
  34. Change in plasma viral load, and viral DNA and mRNA burdens in peripheral blood mononuclear cells from patients infected with HIV-1., 2001
  35. Is human imunodeficiency virus -1 mRNA burdens in peripheral blood mononuclear cells (PBMCs) possible to be anew clinical marker in HIV-1 infected patients?, 1999
  36. The change of HIV-1 RNA copy number in peripheral blood monouclear cells during anti-HIV therapies, 1998
  37. Usefulness of improved measurement of platelet RNA stained with Thiazole Orange: High percentage of TO positive platelets is distinctive feature of ITP, 1997
  38. Evaluation pf thrombopoiesis by the measurement of immature platelets with thiazole orange and serum thrombopoietin concentration in thrombocytopenic disorders, 1997
  39. Usefulness of platelet RNA measurement for the analysis of platelet productive activity and differential diagnosis in various thrombocytopenia, 1996
  40. Usefulness of improved measurement of TO positve platelets is distinctive feature of ITP when compared with chronic thrombocytopenia caused by other disorders, 1996
  41. Chromogeric assay may be more superior to one-stage assay for measuring factor VIII activity?, Naoya Yamasaki,, Kyoko Kajihara, Hiromi Nakagawa, Michiya Yokozaki, Terhisa Fujii, The 79th annual conference of Japan Society of Hematology, Without Invitation, Japanese, Japan Society of Hematology, Osaka, other

Social Activities

History as Committee Members

  1. a director, 2014, The Japanese Society of Transfusion and Cell Therapy

Organizing Academic Conferences, etc.

  1. Chairman, 2014/10, 2014/10
  2. JSTH scientific standardization committee symposium 2019, The chief of hemophilia sub-committee, scientific standardization committee, JSTH, 2019/02, 2019/02

History as Peer Reviews of Academic Papers

  1. 2021, Patient Preference and Adherence, Others, 1
  2. 2021, Trombosis Research, Others, 1
  3. 2021, International Journal of General Medicine, Others, 1
  4. 2021, Internal Medicine, Others, 3
  5. 2021, Journal of Blood Medicine, Editor, Editor, 2
  6. 2020, Journal of Blood Medicine, Editor, Editor
  7. 2020, International Journal of Hematology, Others, reviewer, 3
  8. 2015, Journal of Internal medicine, Others, Peer Reviewer, 2
  9. 2015, International Journal of Hematology, Others, Peer Reviewer, 2
  10. 2015, Haemophilia, Others, Peer Reviewer, 2
  11. 2015, Japanese Journal of Transfusion and Cell Therapy, Others, Peer Reviewer, 1
  12. 2015, Journal of Bone and Mineral Metabolism, Others, Peer Reviewer, 1
  13. 2015, The Japanese Journal of Thrombosis and Hemostasis, Others, Peer Reviewer, 1
  14. 2016, International Journal of hematology, Others, peer reviewer, 3
  15. 2016, Journal of Internal Medicine, Others, peer reviewer, 5
  16. 2017, International journal of hematology, Others, 3
  17. 2017, Internal medicine, Others
  18. 2018, International journal of hematology, Others, Peer Reviewers, 2
  19. 2018, Journal of Blood Transfusion Medicine, Editor, 1
  20. 2018, Trombosis Research, Others, Peer Reviewer, 1